{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:06:39Z","timestamp":1791209199166,"version":"4.1.0"},"reference-count":53,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["GSK Study 112234"],"award-info":[{"award-number":["GSK Study 112234"]}]},{"name":"GSK","award":["NCT00712933"],"award-info":[{"award-number":["NCT00712933"]}]},{"name":"GSK","award":["NCT00724867"],"award-info":[{"award-number":["NCT00724867"]}]},{"name":"GSK","award":["Study 112233"],"award-info":[{"award-number":["Study 112233"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,8,8]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Examine long-term glucocorticoid usage, safety and prevention of organ damage in patients with SLE treated with belimumab plus standard therapy (ST).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This\n                      <jats:italic>post hoc<\/jats:italic>\n                      analysis from three global long-term extension (LTE) studies (BEL112233, BEL112234 and BEL112626) included patients who completed parent studies BLISS-52, BLISS-76 or LBSL02. All patients in the LTEs received open-label belimumab (10\u2009mg\/kg) intravenously every 28 days plus ST. Endpoints included long-term SLE medication use any time after first belimumab dose (in parent or LTE study), organ damage accrual (up to 8 years) and safety (up to 13 years).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Altogether, 1304 patients enrolled in the LTE studies; 1299 received \u22651\u2009dose of belimumab and were included in the modified intent to treat population. Of these, 1221 (94%) patients were female and at enrolment had a mean (SD) age and disease duration of 39.7 (11.6) and 7.2 (6.7) years, respectively. Mean (SD) baseline Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) and Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index (SDI) scores were 8.2 (4.3) and 0.7 (1.2), respectively. The most frequently used SLE concomitant medications at any time after first dose of belimumab were glucocorticoid (GC) (94.1%), antimalarials (74.6%) and immunosuppressants (56.4%). Approximately 50% of patients reduced their GC dose to \u22647.5\u2009mg\/day in the first 3 years, increasing to 73.6% by the end of year 8. Mean (SD) changes in SDI score to year 8 did not exceed 0.3 (0.6). Overall, 97.5% of patients had \u22651 adverse event (AE) up to 13 years. While 40.4% had \u22651 serious AE, the incidence of AEs leading to belimumab discontinuation generally remained low over time (10.7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with SLE treated with belimumab reduced GC use and had minimal to no organ damage progression over 8 years. Robust and consistent safety data up to 13 years support the well-established favourable safety profile of belimumab, with no new safety concerns.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2026-002199","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:30:17Z","timestamp":1791207017000},"page":"e002199","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Belimumab prevention against organ damage over 8 years and safety up to 13 years: three pooled open-label, long-term extension SLE studies"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct00071487","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00583362","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00424476","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410384","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00712933","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00724867","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00583362","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00724867","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00712933","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5177-2076","authenticated-orcid":false,"given":"Zahi","family":"Touma","sequence":"first","affiliation":[{"name":"Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9546-1664","authenticated-orcid":false,"given":"Cristina","family":"Arriens","sequence":"additional","affiliation":[{"name":"Department of Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-0975","authenticated-orcid":false,"given":"Maria G","family":"Tektonidou","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, First Department of Propaedeutic Internal Medicine, Laiko Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Cervera","sequence":"additional","affiliation":[{"name":"Department of Autoimmune Diseases, Hospital Cl\u00ednic, Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer, University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-6031","authenticated-orcid":false,"given":"Roger A","family":"Levy","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, GSK, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hammer","sequence":"additional","affiliation":[{"name":"Immunology Biostatistics, GSK, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2502-1372","authenticated-orcid":false,"given":"Daniel J","family":"Wallace","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"2026100506301345000_13.2.e002199.1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)00398-2"},{"key":"2026100506301345000_13.2.e002199.2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.00316","article-title":"B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice","volume":"7","author":"Parodis","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2026100506301345000_13.2.e002199.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez516"},{"key":"2026100506301345000_13.2.e002199.4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez584"},{"key":"2026100506301345000_13.2.e002199.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep062"},{"key":"2026100506301345000_13.2.e002199.6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/acr.20648","article-title":"Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort","volume":"64","author":"Urowitz","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026100506301345000_13.2.e002199.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.34672"},{"key":"2026100506301345000_13.2.e002199.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205171"},{"key":"2026100506301345000_13.2.e002199.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762"},{"key":"2026100506301345000_13.2.e002199.10","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/acr.25690","article-title":"2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus","volume":"78","author":"Sammaritano","year":"2026","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026100506301345000_13.2.e002199.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-216924"},{"key":"2026100506301345000_13.2.e002199.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303"},{"key":"2026100506301345000_13.2.e002199.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031850","article-title":"Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"10","author":"Murimi-Worstell","year":"2020","journal-title":"BMJ Open"},{"key":"2026100506301345000_13.2.e002199.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.11299"},{"key":"2026100506301345000_13.2.e002199.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.23678"},{"key":"2026100506301345000_13.2.e002199.16","doi-asserted-by":"publisher","DOI":"10.1002\/art.34400"},{"key":"2026100506301345000_13.2.e002199.17","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211028653"},{"key":"2026100506301345000_13.2.e002199.18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2"},{"key":"2026100506301345000_13.2.e002199.19","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/art.40049","article-title":"Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study","volume":"69","author":"Stohl","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026100506301345000_13.2.e002199.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211631"},{"key":"2026100506301345000_13.2.e002199.21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.41900","article-title":"Phase III\/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus","volume":"74","author":"Ginzler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2026100506301345000_13.2.e002199.22","doi-asserted-by":"publisher","DOI":"10.1002\/art.30613"},{"key":"2026100506301345000_13.2.e002199.23","unstructured":"Costenbader K , Abe Y , Arnaud L , et al . Reduction in Glucocorticoid Use in Patients with Systemic Lupus Erythematosus Treated with Belimumab: A Large Pooled Analysis of 5 Placebo-Controlled Studies [abstract]. Arthritis Rheumatol 2021;73."},{"key":"2026100506301345000_13.2.e002199.24","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40744-025-00774-6","article-title":"Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study","volume":"12","author":"Costenbader","year":"2025","journal-title":"Rheumatol Ther"},{"key":"2026100506301345000_13.2.e002199.25","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40744-024-00675-0","article-title":"Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study","volume":"11","author":"Rubin","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026100506301345000_13.2.e002199.26","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000412","article-title":"Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study","volume":"7","author":"Urowitz","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2026100506301345000_13.2.e002199.27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez279"},{"key":"2026100506301345000_13.2.e002199.28","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/art.40439","article-title":"Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States","volume":"70","author":"Furie","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026100506301345000_13.2.e002199.29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214043"},{"key":"2026100506301345000_13.2.e002199.30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/art.40861","article-title":"Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus","volume":"71","author":"Wallace","year":"2019","journal-title":"Arthritis & Rheumatology"},{"key":"2026100506301345000_13.2.e002199.31","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315625119"},{"key":"2026100506301345000_13.2.e002199.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.24699"},{"key":"2026100506301345000_13.2.e002199.33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-096989","article-title":"Patient-reported outcome measured by EQ-5D and influencing factors among patients of systemic lupus erythematosus in China: a multicentre cross-sectional study from CSTAR Registry","volume":"15","author":"Li","year":"2025","journal-title":"BMJ Open"},{"key":"2026100506301345000_13.2.e002199.34","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/acr.24092","article-title":"Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach","volume":"72","author":"Barber","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026100506301345000_13.2.e002199.35","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/art.41253","article-title":"Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting","volume":"72","author":"Gatto","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026100506301345000_13.2.e002199.36","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.2022.13591","article-title":"Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares","volume":"328","author":"Jorge","year":"2022","journal-title":"JAMA"},{"key":"2026100506301345000_13.2.e002199.37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa382"},{"key":"2026100506301345000_13.2.e002199.38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s11883-023-01149-4","article-title":"Atherosclerosis in Systemic Lupus Erythematosus","volume":"25","author":"Tobin","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"2026100506301345000_13.2.e002199.39","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2665-9913(24)00090-0","article-title":"Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries","volume":"6","author":"Bolla","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"2026100506301345000_13.2.e002199.40","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1016\/S2665-9913(20)30355-6","article-title":"Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial","volume":"3","author":"Sheikh","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026100506301345000_13.2.e002199.41","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319860579"},{"key":"2026100506301345000_13.2.e002199.42","doi-asserted-by":"crossref","unstructured":"Seguro L , Negrini A , Pasoto S , et al . Interim analysis of the impact of a recombinant herpes zoster vaccine on systemic lupus erythematosus: a randomized controlled study on immunogenicity, safety and immunosuppressor effects. Arthritis Rheumatol 2025;77. doi:10.29327\/1716874.42-719","DOI":"10.29327\/1716874.42-719"},{"key":"2026100506301345000_13.2.e002199.43","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-025-03482-2","article-title":"Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus: a retrospective cohort study","volume":"27","author":"Cho","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"2026100506301345000_13.2.e002199.44","doi-asserted-by":"crossref","unstructured":"Vollenhoven RV , Bruce IN , Merrill JT , et al . PO:11:294 Five-year safety of belimumab in SLE: insights from the global, prospective, observational SABLE registry. Lupus Sci Med 2026;13. doi:10.1136\/lupus-2026-el.347","DOI":"10.1136\/lupus-2026-el.347"},{"key":"2026100506301345000_13.2.e002199.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.06.017"},{"key":"2026100506301345000_13.2.e002199.46","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313477227"},{"key":"2026100506301345000_13.2.e002199.47","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-017-1234-1","article-title":"Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis","volume":"17","author":"Zhang","year":"2017","journal-title":"BMC Psychiatry"},{"key":"2026100506301345000_13.2.e002199.48","doi-asserted-by":"crossref","unstructured":"Okamoto N , Fujii T , Atsumi T , et al . Safety of intravenous and subcutaneous belimumab in Japanese patients with systemic lupus erythematosus: Final analysis of data from an all-case post-marketing surveillance study. Mod Rheumatol 2026.:roag066. doi:10.1093\/mr\/roag066","DOI":"10.1093\/mr\/roag066"},{"key":"2026100506301345000_13.2.e002199.49","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001747","article-title":"Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison","volume":"7","author":"Brunner","year":"2021","journal-title":"RMD Open"},{"key":"2026100506301345000_13.2.e002199.50","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1177\/09612033221131183","article-title":"Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data","volume":"31","author":"Wallace","year":"2022","journal-title":"Lupus"},{"key":"2026100506301345000_13.2.e002199.51","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001669","article-title":"Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years","volume":"8","author":"Zhang","year":"2022","journal-title":"RMD Open"},{"key":"2026100506301345000_13.2.e002199.52","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/mr\/roab125","article-title":"Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026100506301345000_13.2.e002199.53","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001400","article-title":"Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis","volume":"12","author":"Li","year":"2025","journal-title":"Lupus Sci Med"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2026-002199","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:30:24Z","timestamp":1791207024000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2026-002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,10,5]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/lupus-2026-002199"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2026-002199","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}